The "2-step" method makes liquid chromatography retention-time prediction for small molecules work out of the box, with no retraining for new systems, a direct benefit to drug discovery and natural-product research.
A team combined AI protein structure prediction with high-throughput proteomics to discover molecular-glue degraders that target VAV1, a key immune-signaling protein, as reported by Hanfeng Lin et al. in Nature Communications in 2026.
AI drug discovery company Transcripta Bio and "AI chemistry foundry" Synfini report obtaining a validation-grade lead compound against the MSH3 gene in a matter of weeks, versus an industry benchmark of 12-18 months from hit to candidate nomination.
AI-native pharmaceutical company Talus Bio has launched Ptarmigan-1, billed as the first AI model that can predict small-molecule binding across the entire human proteome without needing three-dimensional structures, and has opened public access.